|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group. Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y,
Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL,
Watkins CL, Armour AA and Fukuoka M: Gefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med.
361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ,
Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and
Meyerson M: EGFR mutations in lung cancer: correlation with
clinical response to gefitinib therapy. Science. 304:1497–1500.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA: Activating mutations in the epidermal growth factor
receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Terai H, Soejima K, Yasuda H, Nakayama S,
Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, Yoda S,
Satomi R, Naoki K and Betsuyaku T: Activation of the FGF2-FGFR1
autocrine pathway: a novel mechanism of acquired resistance to
gefitinib in NSCLC. Mol Cancer Res. 11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheung HH, Lee TL, Rennert OM and Chan WY:
DNA methylation of cancer genome. Birth Defects Res C Embryo Today.
87:335–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heller G, Zielinski CC and
Zöchbauer-Müller S: Lung cancer: from single-gene methylation to
methylome profiling. Cancer Metastasis Rev. 29:95–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilting RH and Dannenberg JH: Epigenetic
mechanisms in tumorigenesis, tumor cell heterogeneity and drug
resistance. Drug Resist Updat. 15:21–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N Engl J Med.
343:1350–1354. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nyce JW: Drug-induced DNA
hypermethylation: a potential mediator of acquired drug resistance
during cancer chemotherapy. Mutat Res. 386:153–161. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taniguchi T, Tischkowitz M, Ameziane N,
Hodgson SV, Mathew CG, Joenje H, Mok SC and D’Andrea AD: Disruption
of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian
tumors. Nat Med. 9:568–574. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen DW, Su A, Liang XJ, Pai-Panandiker A
and Gottesman MM: Reduced expression of small GTPases and
hypermethylation of the folate binding protein gene in
cisplatin-resistant cells. Br J Cancer. 91:270–276. 2004.PubMed/NCBI
|
|
15
|
Ibanez de Caceres I, Cortes-Sempere M,
Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García
C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M,
Belda-Iniesta C and Perona R: IGFBP-3 hypermethylation-derived
deficiency mediates cisplatin resistance in non-small-cell lung
cancer. Oncogene. 29:1681–1690. 2010.PubMed/NCBI
|
|
16
|
Stone A, Valdés-Mora F, Gee JM, Farrow L,
McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL,
Musgrove EA and Nicholson RI: Tamoxifen-induced epigenetic
silencing of oestrogen-regulated genes in anti-hormone resistant
breast cancer. PLoS One. 7:e404662012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeller C, Dai W, Steele NL, Siddiq A,
Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA
and Brown R: Candidate DNA methylation drivers of acquired
cisplatin resistance in ovarian cancer identified by methylome and
expression profiling. Oncogene. 31:4567–4576. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu W, Jin C, Lou X, Han X, Li L, He Y,
Zhang H, Ma K, Zhu J, Cheng L and Lin B: Global analysis of DNA
methylation by Methyl-Capture sequencing reveals epigenetic control
of cisplatin resistance in ovarian cancer cell. PLoS One.
6:e294502011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang X, Monitto CL, Demokan S, Kim MS,
Chang SS, Zhong X, Califano JA and Sidransky D: Identification of
hypermethylated genes associated with cisplatin resistance in human
cancers. Cancer Res. 70:2870–2879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Li W, Li H, Ma Y, He G and Tan G:
Genomic methylation profiling combined with gene expression
microarray reveals the aberrant methylation mechanism involved in
nasopharyngeal carcinoma taxol resistance. Anticancer Drugs.
23:856–864. 2012. View Article : Google Scholar
|
|
21
|
Noro R, Gemma A, Miyanaga A, Kosaihira S,
Minegishi Y, Nara M, Kokubo Y, Seike M, Kataoka K, Matsuda K, Okano
T, Yoshimura A and Kudoh S: PTEN inactivation in lung cancer cells
and the effect of its recovery on treatment with epidermal growth
factor receptor tyrosine kinase inhibitors. Int J Oncol.
31:1157–1163. 2007.PubMed/NCBI
|
|
22
|
Ogawa T, Liggett TE, Melnikov AA, Monitto
CL, Kusuke D, Shiga K, Kobayashi T, Horii A, Chatterjee A, Levenson
VV, Koch WM, Sidransky D and Chang X: Methylation of
death-associated protein kinase is associated with cetuximab and
erlotinib resistance. Cell Cycle. 11:1656–1663. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu J, Wang Y, Duan J, Bai H, Wang Z, Wei
L, Zhao J, Zhuo M, Wang S, Yang L, An T, Wu M and Wang J: DNA
Methylation status of Wnt antagonist SFRP5 can predict the response
to the EGFR-tyrosine kinase inhibitor therapy in non-small cell
lung cancer. J Exp Clin Cancer Res. 31:802012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong
YJ and Feng JF: Blockade of DNA methylation enhances the
therapeutic effect of gefitinib in non-small cell lung cancer
cells. Oncol Rep. 29:1975–1982. 2013.PubMed/NCBI
|
|
25
|
Costa DB, Halmos B, Kumar A, Schumer ST,
Huberman MS, Boggon TJ, Tenen DG and Kobayashi S: BIM mediates EGFR
tyrosine kinase inhibitor-induced apoptosis in lung cancers with
oncogenic EGFR mutations. PLoS Med. 4:1669–1680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
|
|
27
|
Wang Y, Chen L, Huang G, He D, He J, Xu W,
Zou C, Zong F, Li Y, Chen B, Wu S, Zhao W and Wu J: Klotho
sensitizes human lung cancer cell line to cisplatin via PI3k/Akt
pathway. PLoS One. 8:e573912013. View Article : Google Scholar : PubMed/NCBI
|
